SCHEMBL261233

SCHEMBL261233

COC1CCN(Cc2c[nH]c(C=O)c2)CC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 2/20 0.39
OPRM1 P35372 1/20 0.38
OPRK1 P41145 1/20 0.38
LTA4H P09960 1/20 0.38
PDE1B Q01064 1/20 0.36
DRD2 P14416 3/20 0.36
DRD4 P21917 3/20 0.36
DRD3 P35462 3/20 0.36
MAP4K4 O95819 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
EHMT2 Q96KQ7 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
PDE2A O00408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260376 0.79 HRH3 (0.42) DRD2DRD4DRD3HRH3
SCHEMBL260817 0.79 MC4R (0.45) DRD2DRD4DRD3
SCHEMBL260905 0.78 HRH3 (0.46) DRD2DRD4DRD3HRH3
SCHEMBL259925 0.76 HRH3 (0.45) DRD2DRD4DRD3HRH3
SCHEMBL259653 0.74 ICAM1 (0.34) DRD2DRD4DRD3
SCHEMBL260714 0.73 DRD2 (0.34) DRD2DRD4DRD3
SCHEMBL260081 0.72 FGFR1 (0.53) OPRM1OPRK1MAP4K4
SCHEMBL260037 0.71 GRM2 (0.40) DRD2DRD4DRD3SIGMAR1
SCHEMBL8096431 0.68 ACHE (0.66) OPRM1OPRK1LTA4HDRD2DRD4
SCHEMBL12082512 0.67 ALDH1A1 (0.56) OPRM1OPRK1LTA4HHRH3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 TLR7 2843/4885OPRM1 287/4885OPRK1 419/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 TLR7 2843/4885OPRM1 287/4885OPRK1 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.